Carotid Artery Stenosis Clinical Trial
— SLICE-CEAOfficial title:
Study of Lipids Inside the Carotid With Evolocumab: A Randomized Trial of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology Prior to Carotid EndArterectomy (SLICE-CEA CardioLink-8 Study)
This is a multicenter, randomized, open label study with blinded outcome assessment to evaluate the impact of additional/intensive LDL-cholesterol reduction with evolocumab on carotid artery atherosclerotic plaques in higher risk subjects with severe asymptomatic but vulnerable plaques.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | May 2022 |
Est. primary completion date | April 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years and older |
Eligibility | Inclusion Criteria: 1. Age = 40 years old 2. Significant (70-99%) carotid artery stenosis on one side, as measured by duplex ultrasound or angiogram 3. Asymptomatic carotid stenosis (no history of ipsilateral stroke or TIA within 180 days) 4. Deemed to be fit for carotid endarterectomy 5. At least one of the following high-risk features: (a) prior stroke >6months prior to randomization; (b) peripheral artery disease; (c) current smoker; (d) type 2 diabetes; (e) eGFR = 30 mL/min/1.73m2 and <60 ml/min/1.73m2; (f) hsCRP > 2mg/L in the absence of alternative known causes of hsCRP elevations including autoimmune diseases or active infections. 6. On a moderate to high intensity statin therapy (defined as atorvastatin 40-80mg daily, rosuvastatin 20-40mg or simvastatin 40mg daily) unless a lower dose, or another statin or non-statin therapy is clinically justified Exclusion Criteria: 1. Contraindications for MRI (pacemaker; neurostimulator; non-removable metal fragments in the eye; etc.) 2. Patients in whom additional lowering of LDL-C with evolocumab is deemed to be clinically inappropriate 3. Currently taking simvastatin >40mg/day 4. High risk comorbidities such as severe heart failure, severe COPD, severe renal disease, known severe hepatic impairment, unstable coronary syndrome, and/or advanced dementia 5. eGFR <30 mL/min/1.73m2 6. Current, prior within past year, or known planned use of PCSK9 inhibition treatment 7. Known intolerance or allergy to evolocumab or other PCSK9 inhibitors 8. Known latex allergy 9. Women who are pregnant or breastfeeding 10. Women of child bearing potential who are unwilling to use proper family planning or birth control methods to avoid pregnancy. Women are considered post-menopausal and not of childbearing potential after 12 months of natural (spontaneous) amenorrhea or have had a surgical procedure such as hysterectomy which makes pregnancy impossible 11. Inability to comply with protocol-required study visits or procedures, including administration of study drug 12. Severe concomitant disease that is expected to reduce life expectancy to less than 5 years 13. Participation in another investigational device or drug study which is likely to affect the primary outcome, within 30 days of planned initiation of study drug Additional Inclusion Criteria If all eligibility criteria listed above are met, participants with only one high risk feature will undergo a time-of-flight MR angiogram, where one additional inclusion criteria will be assessed to confirm eligibility: 1. Evidence of IPH on MRI |
Country | Name | City | State |
---|---|---|---|
Canada | North York Diagnostic and Cardiac Centre | North York | Ontario |
Canada | East Toronto Vascular Clinic | Toronto | Ontario |
Canada | St. Michael's Hospital | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
Canadian Medical and Surgical Knowledge Translation Research Group | Amgen |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Plaque Histology and Morphology | Obtained at time of CEA | At the end of treatment (average of 6 months) | |
Other | Lipid Levels | Serum lipid levels | Baseline to end of treatment (average of 6 months) | |
Primary | Change in lipid rich necrotic core (LRNC) volume | As measured by MRI | Baseline to end of treatment (average of 6 months) | |
Secondary | Change in vessel wall volume | As measured by MRI | Baseline to end of treatment (average of 6 months) | |
Secondary | Change in vessel lumen volume | As measured by MRI | Baseline to end of treatment (average of 6 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03931161 -
Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1)
|
Phase 4 | |
Recruiting |
NCT03353103 -
Imaging of Unstable Carotid Plaque in Patient Referred to Endarterectomy
|
Phase 2 | |
Completed |
NCT03996148 -
Time to Post-Anesthesia Neurological Evaluation With Three Different Anesthetic Techniques
|
Phase 4 | |
Recruiting |
NCT05968053 -
Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
|
||
Completed |
NCT00597974 -
Neurological Outcome With Carotid Artery Stenting
|
N/A | |
Completed |
NCT00318851 -
Carotid Artery Stenting With Protection Registry
|
Phase 3 | |
Active, not recruiting |
NCT05293067 -
Troponin In Carotid Revascularization
|
||
Completed |
NCT03133429 -
Clinical Study to Evaluate the Safety and Effectiveness of MER® Stents in Carotid Revascularisation.
|
N/A | |
Recruiting |
NCT01440036 -
The Correlation Between the Enzyme Paraoxigenase 1 (PON1) to Carotid Artery Atheromatous Plaque
|
N/A | |
Completed |
NCT00417963 -
ViVEXX Carotid Revascularization Trial (VIVA)
|
Phase 3 | |
Completed |
NCT00177346 -
A Randomized Trial of Carotid Artery Stenting With and Without Cerebral Protection
|
N/A | |
Recruiting |
NCT05574972 -
Timing Carotid Stent Clinical Study for the Treatment of Carotid Artery Stenosis(Timing Trial)
|
N/A | |
Recruiting |
NCT02476396 -
Structural Stability of Carotid Plaque and Symptomatology
|
||
Completed |
NCT05451485 -
VFI in Healthy Vessels
|
||
Recruiting |
NCT06033963 -
Safety and Efficacy of Remote Ischemic Conditioning in Patients With Carotid Artery Stenosis Receiving Carotid EndArterectomy
|
N/A | |
Not yet recruiting |
NCT02224209 -
Comparison of Staged Angioplasty and Routine Single-stage Stenting (CAS) in the Treatment of Carotid Artery Stenosis
|
Phase 4 | |
Completed |
NCT02006095 -
Neuroimaging Correlates of Memory Decline Following Carotid Interventions
|
||
Terminated |
NCT01236508 -
Relation of Carotid Artery Plaque Inflammation, Covert Stroke and White Matter Disease
|
Phase 4 | |
Recruiting |
NCT05126238 -
A Lithium-Based Medication to Improve Neurological Outcomes After Surgical Carotid Reconstruction
|
Phase 3 | |
Recruiting |
NCT06170580 -
Improved Image Quality for Assessment of Carotid Artery Stenosis by Ultrafast Ultrasound FLOW Imaging
|